Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 3, 2015, Pages 561-568.e1

  Patel, Niraj S ^a   Doycheva, Iliana ^a   Peterson, Michael R ^a   Hooker, Jonathan ^a   Kisselva, Tatiana ^a   Schnabl, Bernd ^a   Seki, Ekihiro ^a   Sirlin, Claude B ^a   Loomba, Rohit ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

Author keywords

Biomarker; Noninvasive; Response to treatment; Steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; COLESEVELAM; GLUCOSE; HEMOGLOBIN A1C; FAT;

ADIPOSE TISSUE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; FAT CONTENT; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FAT; LIVER HISTOLOGY; LIVER WEIGHT; MALE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTON DENSITY FAT FRACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY ANALYSIS; WEIGHT GAIN; WEIGHT REDUCTION; AGED; BIOPSY; COMPLICATION; CYTOCHEMISTRY; LIVER; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BIOPSY; BODY MASS INDEX; FATS; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WEIGHT LOSS;

EID: 84925304127     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.08.039     Document Type: Article

References (41)

1. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
2. Loomba R., Sanyal A.J. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013, 10:686-690.
3. Bellentani S., Saccoccio G., Masutti F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000, 132:112-117.
4. Kotronen A., Peltonen M., Hakkarainen A., et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009, 137:865-872.
5. Loomba R., Abraham M., Unalp A., et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012, 56:943-951.
6. Zarrinpar A., Loomba R. Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012, 36:909-921.
7. Williams C.D., Stengel J., Asike M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140:124-131.
8. Bellentani S., Scaglioni F., Marino M., et al. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010, 28:155-161.
9. Bhala N., Angulo P., van der Poorten D., et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011, 54:1208-1216.
10. Singh S., Allen A.M., Wang Z., et al. Fibrosis progression in nonalcoholic fatty liver versus nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2014.
11. Ratziu V., Giral P., Jacqueminet S., et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008, 135:100-110.
12. Belfort R., Harrison S.A., Brown K., et al. Aplacebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. NEngl J Med 2006, 355:2297-2307.
13. Sanyal A.J., Chalasani N., Kowdley K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. NEngl J Med 2010, 362:1675-1685.
14. Lincoff A.M., Wolski K., Nicholls S.J., et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180-1188.
15. Boettcher E., Csako G., Pucino F., et al. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2012, 35:66-75.
16. Lavine J.E., Schwimmer J.B., Van Natta M.L., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011, 305:1659-1668.
17. Miller E.R., Pastor-Barriuso R., Dalal D., et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005, 142:37-46.
18. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55:2005-2023.
19. Le T.A., Chen J., Changchien C., et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012, 56:922-932.
20. Harrison S.A., Fecht W., Brunt E.M., et al. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology 2009, 49:80-86.
21. Promrat K., Kleiner D.E., Niemeier H.M., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51:121-129.
22. Mathurin P., Hollebecque A., Arnalsteen L., et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009, 137:532-540.
23. Mummadi R.R., Kasturi K.S., Chennareddygari S., et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008, 6:1396-1402.
24. Lazo M., Solga S.F., Horska A., et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 2010, 33:2156-2163.
25. Browning J.D., Baker J.A., Rogers T., et al. Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr 2011, 93:1048-1052.
26. Wong V.W., Chan R.S., Wong G.L., et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. JHepatol 2013, 59:536-542.
27. Patel N.S., Peterson M.R., Brenner D.A., et al. Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013, 37:630-639.
28. Patel N.S., Peterson M.R., Lin G.Y., et al. Insulin resistance increases MRI-estimated pancreatic fat in nonalcoholic fatty liver disease and normal controls. Gastroenterol Res Pract 2013, 2013:498296.
29. Reeder S.B., Cruite I., Hamilton G., et al. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. JMagn Reson Imaging 2011, 34. spcone.
30. Hines C.D., Frydrychowicz A., Hamilton G., et al. T(1) independent, T(2) (*) corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accurate and precise measure of hepatic steatosis. JMagn Reson Imaging 2011, 33:873-881.
31. Noureddin M., Lam J., Peterson M.R., et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013, 58:1930-1940.
32. Santini F., Giannetti M., Mazzeo S., et al. Ultrasonographic evaluation of liver volume and the metabolic syndrome in obese women. JEndocrinol Invest 2007, 30:104-110.
33. Giannetti M., Piaggi P., Ceccarini G., et al. Hepatic left lobe volume is a sensitive index of metabolic improvement in obese women after gastric banding. Int J Obes (Lond) 2012, 36:336-341.
34. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
35. Noureddin M., Yates K.P., Vaughn I.A., et al. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 2013.
36. Kuhn J.P., Hernando D., Mensel B., et al. Quantitative chemical shift-encoded MRI is an accurate method to quantify hepatic steatosis. JMagn Reson Imaging 2014, 39:1494-1501.
37. Hines C.D., Yu H., Shimakawa A., et al. T1 independent, T2* corrected MRI with accurate spectral modeling for quantification of fat: validation in a fat-water-SPIO phantom. JMagn Reson Imaging 2009, 30:1215-1222.
38. Liu C.Y., McKenzie C.A., Yu H., et al. Fat quantification with IDEAL gradient echo imaging: correction of bias from T(1) and noise. Magn Reson Med 2007, 58:354-364.
39. Zhong X., Nickel M.D., Kannengiesser S.A., et al. Liver fat quantification using a multi-step adaptive fitting approach with multi-echo GRE imaging. Magn Reson Med 2013.
40. Johnson N.A., Sachinwalla T., Walton D.W., et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009, 50:1105-1112.
41. Loomba R., Wesley R., Pucino F., et al. Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials. Clin Gastroenterol Hepatol 2008, 6:1243-1248.